Rosetta Genomics Ltd. develops and commercializes microRNAs based diagnostic tests and therapeutics. MicroRNAs are a group of genes that are produced using instructions encoded in DNA. The company offers diagnostic tests, including Rosetta Cancer Origin test, a microRNA-based diagnostic to identify 42 tumor types that include carcinomas, soft tissue tumors, lymphoma, and other malignancies; Rosetta Mesothelioma test to differentiate mesothelioma, a cancer connected to asbestos exposure and other risk factors, from other carcinomas in the lung and pleura; Rosetta Lung Cancer test, a lung cancer classification test for cytology samples; and Rosetta Kidney Cancer test, a microRNA-based kidney tumor classification test for pathology samples. It is also developing a test for the differential diagnosis of indeterminate thyroid fine needle aspirate samples; blood or urine based microRNA biomarkers to develop a diagnostic test for chronic kidney rejection; blood-based microRNA biomarkers to develop a diagnostic test for early diagnosis of heart failure and refined risk stratification of patients following myocardial infarction; tissue-based microRNA biomarkers to develop a test for the risk stratification of patients with non-muscle-invasive bladder cancer; tissue-based microRNA biomarkers to develop a test for the pre-surgical risk stratification of patients with endometrial cancer; and microRNA-based diagnostic test for the early diagnosis of Alzheimer s disease. The company distributes its products primarily in Australia, Canada, Greece, India, Israel, New Zealand, Qatar, Romania, Saudi Arabia, Singapore, Turkey, and the United Arab Emirates. Rosetta Genomics Ltd. was founded in 2000 and is based in Rehovot, Israel.